You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 5015 results
  1. Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).

    SBC: MAKSCIENTIFIC            Topic: NIDA

    OTHER PROJECT INFORMATION – Unit 7 – Project Summary/Abstract This project addresses the growing need for medications for cannabis use disorder (CUD) which, in the absence of approved medications, is a major focus of NIDA’s mission. Currently available cannabinergic-based treatments for CUD include the directly acting CB1 agonists, e.g., Δ9-THC or nabilone, which have been reported to reduc ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Field Instrument for Assessment of Arsenic Exposure

    SBC: GINER INC            Topic: R

    Project Summary Human exposure to toxic heavy metals existing in drinking water, food, and the environment is an area of increasing national and international concern. Heavy metals are significant environmental pollutants because they tend to persist, bioaccumulate and can result in serious adverse acute or chronic health effects after ingested or inhaled. Traditionally, trace metals are measured ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections

    SBC: Rational Vaccines, Inc.            Topic: NIAID

    PROJECT SUMMARY: Herpes Simplex Virus (HSV) infections are common, infecting more than half of the world’s population. While most cases of genital herpes are caused by HSV type 2 (HSV-2), it is estimated that more than 150 million people aged 15-49 have genital HSV type 1 (HSV-1) infections. Although several vaccines have been evaluated for preventing/treating HSV infections, none have received ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical validation of small molecule immunomodulators for the treatment of Crohn's disease

    SBC: PROMAKHOS THERAPEUTICS INC            Topic: 300

    Project Summary Crohn’s disease is a debilitating and chronic inflammatory disorder of the gastrointestinal tract characterized by aberrant healing and intestinal stricturing. In the US, rt500,000 patients suffer from Crohn’s disease and over 30,000 patients are newly diagnosed each year. No curative treatments exist. Instead, current treatments focus on managing symptoms and reducing the occu ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Rumbo: An Integrated Mobile and Web-Based Application to Overcome Barriers to Receive Substance Use Disorder (SUD) Treatment and Improve Outcomes for Spanish-Speaking, Hispanic and Latinx Individuals

    SBC: VOLVER HEALTH LLC            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT Substance use is a significant problem among Latinx and Hispanics due to the disproportionate number of physical harms and negative consequences associated with substance use relative to other racial/ethnic groups. However, Hispanics are less likely than other racial/ethnic groups to seek treatment for substance use, regardless of the substance(s) they use, and only 75% as ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Improved optimization of covalent ligands using a novel implementation of quantum mechanics suitable for large ligand/protein systems.

    SBC: QUANTUM SIMULATION TECHNOLOGIES INC            Topic: 400

    Project Summary The value of computational chemistry to commercial drug discovery is now well-established. Virtual screening (including molecular docking) now jumpstarts most discovery efforts. Tools such as molecular dynamics and free energy perturbation are increasingly used to inform the later stages of lead refinement. The growing importance of computational structure-based methods has influen ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Consumer-Therapist-Connector: Increasing Access to Quality Behavioral Healthcare

    SBC: OUTCOME REFERRALS INC            Topic: 104

    ABSTRACT The United States is experiencing a major mental health crisis. Per recent reports in the New York Times and The Washington Post, the gap between need and access to behavioral health services is rapidly increasing. There is an urgent need to solve both the access and quality problems with behavioral healthcare. With COVID and other stressors, 76% of surveyed employees are reporting at lea ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. New generation of catheters for treatment of atrial fibrillation

    SBC: LUXMED SYSTEMS INC            Topic: NHLBI

    ABSTRACT Atrial fibrillation (AF) remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality primarily due to poor hemodynamic performance and often stroke. One of the primary options to treat AF is cardiac ablation where the physician applies radiofrequency energy via percutaneous catheters to form a series of ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. First-in-class TREM-1 inhibitors for neovascular retinal diseases

    SBC: SIGNABLOK, INC.            Topic: 100

    Project Summary/Abstract Retinal neovascularization (RNV) is a major cause of vision loss in retinopathy of prematurity (ROP), diabetic retinopathy (DR) and retinal vein occlusion. In the US, about 16,000 of premature infants are affected by ROP annually and about 4.1 million adults years have DR. Complications of conventional treatments suggest an unmet need for new therapies. The long-term objec ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease

    SBC: VINCERE BIOSCIENCES INC            Topic: 999

    ABSTRACT Existing treatments for Parkinson’s disease (PD), which affects 10 million people worldwide, primarily augment dopaminergic neurotransmission to provide symptomatic benefit. No current therapy can slow or stop the progression of PD. We propose a drug discovery platform to develop small molecules targeting the parkin-USP30 mitophagy pathway, which represents a key regulator of mitochondr ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government